| Literature DB >> 34483622 |
Hussein Mohamoud1, Senait Tadesse2, Awoke Derbie2,3,4.
Abstract
BACKGROUND: The emergence and spread of antimicrobial resistance (AMR) among uropathogens is increasing, especially in resource limited settings due to a number of reasons. The production of Extended Spectrum β-Lactamase (ESBL) by some strains of E. coli and methicillin resistant Staphylococcus species, limits the choice of antimicrobials in the treatment of urinary tract infection (UTI) globally. However, little is known about the type of uropathogenes and their current AMR profile among pregnant women in Hargeisa, Somaliland.Entities:
Keywords: Antimicrobial resistance; Bacteriuria; Edna Adan Hospital; Hargeisa; Urinary tract infection; pregnant women
Mesh:
Substances:
Year: 2021 PMID: 34483622 PMCID: PMC8365499 DOI: 10.4314/ejhs.v31i3.22
Source DB: PubMed Journal: Ethiop J Health Sci ISSN: 1029-1857
Socio-demographic Characteristics of Study Participants in Edna Adan Hospital, May, 2019
| Variable | Number(%) |
|
| |
| 15–25 | 175 (46.5) |
| 26–35 | 183(48.7) |
| 36–45 | 18(4.8) |
|
| |
| Urban | 344(91.5) |
| Rural | 32(8.5) |
|
| |
| Unable to read and write | 135(35.9) |
| Only read and write | 52(13.8) |
| Primary School Completed | 44(11.7) |
| Secondary School Completed | 62(16.5) |
| University or College Completed | 83(22.1) |
|
| |
| Less Than 200 USD | 161(42.8) |
| 200–400 USD | 82 (21.8) |
| 400–600 USD | 101(26.9) |
| 600–800 USD | 12(3.2) |
| Greater Than 800 USD | 20(5.3) |
|
| |
| Multigravida | 287(76.3) |
| Primigravida | 89(23.7) |
|
| |
| Nulipara | 70 (18.6) |
| One | 67()17.8 |
| Multipara | 239(63.6) |
|
| |
| First Trimester | 88(23.4) |
| Second trimester | 127(33.8) |
|
| |
| Third trimester | 161(42.8) |
Clinical characteristic of the study participants at Edna Adan Hospital, May, 2019
| Characteristics | Yes, n (%) | No, n (%) |
| Dysuria | 148(39.4) | 228(60.6) |
| Increased Frequency | 92(24.5) | 284(75.5) |
| Urgency | 93(24.7) | 283(75.3) |
| Hemauria | 19(5.1) | 357(94.9) |
| Fever & Chills | 89(23.7) | 287(76.3) |
| Flank Pain | 80(21.3) | 296(78.7) |
| History of Catherization | 40(10.6) | 336(89.4) |
| History of UTI | 147(39.1) | 229(60.9) |
| History of Diabetes Mellitus | 28(7.4) | 348(92.6) |
| History of Hospitalization | 25(6.6) | 35 (93.4) |
| History of Antibiotic use | 86(22.9) | 290(77.1) |
Figure 1Frequency and type distribution of the identified uropathogens among pregnant women at EAH, 2019.
Proportion of ESBL production among the isolates (n=79), May 2019
| Type of the Isolates | Number | % | ESBL producers | Non-ESBL producers |
|
| 36 | 45.5 | 14(38.8) | 22(61.2) |
|
| 16 | 20.3 | 5(31.3) | 11(68.5) |
|
| 7 | 8.9 | 3(42.9) | 4(57.1) |
|
| 5 | 6.3 | 1(20) | 4(80) |
|
| 9 | 11.4 | - | 9 (100) |
|
| 2 | 2.5 | - | 2 (100) |
|
| 3 | 3.8 | 1(33.3) | 2(66.7) |
|
| 1 | 1.3 | 1(100) | 0 |
|
| ||||
| Total | 79 | 100.0 | 25 (31.6) | 54 (68.4) |
Antimicrobial Resistance profile of the bacteria uropathogens among pregnant women at Edna Adan Hospital, May 2019
| Antibiotics | Bacterial Isolates | |||||||
|
| ||||||||
|
| K. |
| S. aureus |
|
| CoNS |
| |
| Ampicillin | 18(50 %) | 14(87.7 %) | 5(72 %) | 7(33 %) | 2(40 %) | 2(34.7%) | 1(50 %) | 0(0 %) |
| Amoxicillin | 21(59 %) | 7(44 %) | 6(86 %) | 4(45.4 %) | 2(60 %) | 0(0.00 %) | 0(0.00%) | 0(0.00 %) |
| Amxclavulanic acid | 32(11.1%) | 0(0.00%) | 3(57.1 %) | 0(0.00 %) | 0(0.00 %) | 0(0.00%) | 0(0.00%) | 0(0.00 %) |
| Nitrofurantoin | 0(0.00 %) | 0(0.00 %) | 0(0.00 %) | 0(0.00 %) | 0(0.00 %) | 0(0.00%) | 1(50 %) | 0(0.00 %) |
| Ceftazidime | 5(13.9%) | 6(37.5%) | 4(57.1%) | 1(11.1 %) | 0(0.00 %) | 0(0.00%) | 0(0.0 %) | 0(0.00 %) |
| Norfloxacin | 28(22.3 %) | 5(31.2%) | 3(57.1 %) | 0(0.00 %) | 3(40 %) | 0(0.00 %) | 0(0.0 %) | 0(0.00 %) |
| Cefotaxime | 22(61.1.8%) | 9(43.6 %) | 4(57.1 %) | 0(0.00 %) | 0(0.00%) | 0(0.00 %) | 1(50 %) | 0(0.00 %) |
| Cephalexin | 17(47.2 %) | 9(43.6%) | 3(42.9 %) | 0(0.00 %) | 1(80 %) | 1(33.3%) | 0(0.00%) | 0(0.00 %) |
|
| ||||||||
| Ceftriaxone | 30(83.3 %) | 14(87.5 %) | 0(0.00 %) | 9(100 %) | 4(80 %) | 3(100 %) | 1(50 %) | 0(0.00 %) |